SEC Form SCHEDULE 13G filed by Inventiva S.A.

$IVA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $IVA alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
Perceptive Advisors LLC
 
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:03/26/2025
 
Joseph Edelman
 
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:03/26/2025
 
Perceptive Life Sciences Master Fund, Ltd.
 
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:03/26/2025
Get the next $IVA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IVA

DatePrice TargetRatingAnalyst
2/21/2025$10.00Buy
TD Cowen
11/12/2024$3.00Neutral
UBS
10/27/2023$12.00Buy
Canaccord Genuity
5/31/2023$11.00Buy
ROTH MKM
5/19/2023Sell → Buy
Societe Generale
3/17/2023$27.00Buy
Stifel
11/15/2022Buy → Sell
Societe Generale
11/22/2021$40.00 → $42.00Buy
HC Wainwright & Co.
More analyst ratings

$IVA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

    The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfunction and fibrosis, and by directly targeting the splanchnic vasculature through its anti-angiogenetic effectsThese findings suggest that lanifibranor may be a promising therapeutic candidate that could potentially address PH-related complications typically associated with MASLD, MASH, and other advanced chronic liver diseases, including cirrhosis Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Par

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IVA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IVA
SEC Filings

See more

$IVA
Leadership Updates

Live Leadership Updates

See more
  • Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

    Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024.   Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH.   Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

    Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva announces the nomination of Andre Turenne as Director

    Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IVA
Financials

Live finance-specific insights

See more
  • Inventiva reports its 2024 full year results and provides a business update

    Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

    Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

    Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.Last patient randomization is anticipated in the first half of 20

    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IVA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more